AUTHORS
Lauren Appell, MD, MS, Giorgio Ottaviano2, Sarthak Kumar3, Mouad Abouqateb4, Kwang Wooahn, PhD5, Peter Bader, MD PhD6, Bernd Gruhn7, Kris Mahadeo, MD, MPH8, Caridad Martinez9, Erin Eileen Doherty, MD10, Parinda Mehta, MD11, Christine Phillips, MD12, Hemalatha Geetharani Rangarajan I, MD13, Akshay Sharma Jr, MBBS14, Takuto Takahashi, MD, PhD15, Larisa Broglie, MD, MS16, Krzysztof Kalwak, PhD, DSc17, Adriana Balduzzi, MD18, Seth Rotz, MD19
AFFILIATIONS
1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
3 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 EBMT, Paris, France
5 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Universitätsklinikum Frankfurt, Frankfurt, Germany
7 Jena University Hospital, Jena, Germany
8 Duke University, Durham, North Carolina, United States
9 Baylor College of Medicine Center for Cell and Gene Therapy, Houston, United States
10 Baylor College of Medicine Center for Cell and Gene Therapy, Houston, United States
11 Cincinnati Children's Hospital, Cincinnati, Ohio, United States
12 Cincinnati Children's Hospital, Cincinnati, Ohio, United States
13 Nationwide Children's Hospital, Columbus, Ohio, United States
14 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
15 Dana-Farber Cancer Institute, Minneapolis, Minnesota, United States
16 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
17 Wroclaw Medical University, Wroclaw, Poland
18 IRCCS San Gerardo Dei Tintori, Villasanta, Italy
19 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Background: Children with Down syndrome (DS) and relapsed/refractory (R/R) acute myeloid leukemia (AML) have historically poor outcomes following allogeneic hematopoietic cell transplantation (HCT), with prior studies reporting 3-year overall survival (OS) of only 21%, driven by both high transplant-related mortality (TRM) and relapse. Whether outcomes have improved in the modern era with advances in supportive care, conditioning regimens, and donor selection is unknown.
Methods: We conducted a retrospective, multicenter analysis using combined Center for International Blood and Marrow Transplant Research (CIBMTR) and European Society for Blood and Marrow Transplantation (EBMT) registry data of children (age <18 years) with DS and AML who underwent first allogeneic HCT between 2000 and 2023. The primary objective was to compare 2-year OS between treatment eras (2000–2009 vs. 2010–2023). Secondary endpoints included TRM, disease-free survival (DFS), cumulative incidence of relapse (CIR), and GVHD. Kaplan-Meier and cumulative incidence methods were used.
Results: Sixty-eight patients were identified (2000–2009: n=27; 2010–2023: n=41). Median age was 3 years (range 0.4–13); 96% were aged 0–9. Disease status at HCT was CR1 (24%), CR2+ (43%), refractory/active disease (31%), and not reported (3%). Conditioning was myeloablative (MAC) in 75% and reduced-intensity (RIC) in 24%. Graft sources included bone marrow (46%), cord blood (35%), and peripheral blood (19%). Median follow-up of survivors was 95 months (range 1–208).
Two-year OS significantly improved from 25.9% (95% CI: 11.5–43.8%) in 2000–2009 to 56.8% (95% CI: 41.2–71.8%) in 2010–2023 (p=0.008). Two-year DFS also improved from 22.2% (95% CI: 8.9–39.5%) to 51.9% (95% CI: 36.4–67.3%) (p=0.030). Two-year TRM trended lower in the modern era (25.9% vs. 15.2%, p=0.300), as did 2-year CIR (51.9% vs. 32.9%, p=0.193), though neither reached statistical significance. No significant difference in OS was observed by conditioning intensity (MAC 45.1% vs. RIC 43.8%, p=0.777).
Conclusions: This combined CIBMTR/EBMT analysis represents the largest reported cohort of children with DS-AML undergoing allogeneic HCT. We demonstrate that 2-year OS more than doubled in the modern era, improving from 26% to 57%, with parallel improvements in DFS. These findings establish that allogeneic HCT is an effective therapeutic option for children with R/R DS-AML — a population in whom transplant was previously associated with dismal outcomes. Improvements in survival likely reflect multiple advances in transplantation practice over time, including supportive care, donor selection, and transplant approaches, although the contribution of individual factors cannot be determined from this analysis. These data support the consideration of HCT as a viable curative strategy for children with DS and R/R AML.
DISCLOSURES
Lauren Appell, MD, MS: No relevant conflicts of interest to declare.